vs

Side-by-side financial comparison of CSG SYSTEMS INTERNATIONAL INC (CSGS) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $323.1M, roughly 1.9× CSG SYSTEMS INTERNATIONAL INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.2%, a 32.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 2.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.6%).

CSG Holding Limited, formerly China Southern Glass Holding Limited, is the largest architectural glass manufacturer in China. It is involved in manufacturing and selling glass products, such as float glass, architectural glass, display glass, automotive glass, coated glass, mirrors, color filter glass, solar glass and conservation glass.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CSGS vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.9× larger
RPRX
$622.0M
$323.1M
CSGS
Growing faster (revenue YoY)
RPRX
RPRX
+2.7% gap
RPRX
4.8%
2.0%
CSGS
Higher net margin
RPRX
RPRX
32.3% more per $
RPRX
34.4%
2.2%
CSGS
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
4.6%
CSGS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSGS
CSGS
RPRX
RPRX
Revenue
$323.1M
$622.0M
Net Profit
$7.0M
$214.2M
Gross Margin
50.0%
Operating Margin
9.0%
62.4%
Net Margin
2.2%
34.4%
Revenue YoY
2.0%
4.8%
Net Profit YoY
-79.7%
2.9%
EPS (diluted)
$0.24
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSGS
CSGS
RPRX
RPRX
Q4 25
$323.1M
$622.0M
Q3 25
$303.6M
$609.3M
Q2 25
$297.1M
$578.7M
Q1 25
$299.5M
$568.2M
Q4 24
$316.7M
$593.6M
Q3 24
$295.1M
$564.7M
Q2 24
$290.3M
$537.3M
Q1 24
$295.1M
$568.0M
Net Profit
CSGS
CSGS
RPRX
RPRX
Q4 25
$7.0M
$214.2M
Q3 25
$20.5M
$288.2M
Q2 25
$12.3M
$30.2M
Q1 25
$16.1M
$238.3M
Q4 24
$34.5M
$208.2M
Q3 24
$19.1M
$544.0M
Q2 24
$13.8M
$102.0M
Q1 24
$19.5M
$4.8M
Gross Margin
CSGS
CSGS
RPRX
RPRX
Q4 25
50.0%
Q3 25
48.1%
Q2 25
49.5%
Q1 25
48.4%
Q4 24
51.3%
Q3 24
49.4%
Q2 24
47.3%
Q1 24
46.5%
Operating Margin
CSGS
CSGS
RPRX
RPRX
Q4 25
9.0%
62.4%
Q3 25
10.0%
70.1%
Q2 25
10.0%
36.3%
Q1 25
9.8%
94.0%
Q4 24
13.4%
60.9%
Q3 24
10.8%
Q2 24
8.8%
50.2%
Q1 24
10.8%
-13.0%
Net Margin
CSGS
CSGS
RPRX
RPRX
Q4 25
2.2%
34.4%
Q3 25
6.7%
47.3%
Q2 25
4.1%
5.2%
Q1 25
5.4%
41.9%
Q4 24
10.9%
35.1%
Q3 24
6.5%
96.3%
Q2 24
4.8%
19.0%
Q1 24
6.6%
0.8%
EPS (diluted)
CSGS
CSGS
RPRX
RPRX
Q4 25
$0.24
$0.49
Q3 25
$0.73
$0.67
Q2 25
$0.44
$0.07
Q1 25
$0.57
$0.55
Q4 24
$1.20
$0.46
Q3 24
$0.67
$1.21
Q2 24
$0.48
$0.23
Q1 24
$0.68
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSGS
CSGS
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$180.0M
$618.7M
Total DebtLower is stronger
$539.5M
$9.0B
Stockholders' EquityBook value
$283.7M
$9.7B
Total Assets
$1.5B
$19.6B
Debt / EquityLower = less leverage
1.90×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSGS
CSGS
RPRX
RPRX
Q4 25
$180.0M
$618.7M
Q3 25
$158.4M
$938.9M
Q2 25
$145.9M
$631.9M
Q1 25
$136.0M
$1.1B
Q4 24
$161.8M
$929.0M
Q3 24
$118.4M
$950.1M
Q2 24
$110.4M
$1.8B
Q1 24
$120.8M
$843.0M
Total Debt
CSGS
CSGS
RPRX
RPRX
Q4 25
$539.5M
$9.0B
Q3 25
$538.6M
$8.9B
Q2 25
$537.8M
$8.0B
Q1 25
$537.6M
$7.6B
Q4 24
$538.5M
$7.6B
Q3 24
$539.5M
$7.6B
Q2 24
$540.5M
$7.6B
Q1 24
$541.5M
$6.1B
Stockholders' Equity
CSGS
CSGS
RPRX
RPRX
Q4 25
$283.7M
$9.7B
Q3 25
$289.5M
$9.6B
Q2 25
$290.7M
$9.5B
Q1 25
$283.1M
$9.8B
Q4 24
$282.6M
$10.3B
Q3 24
$288.4M
$10.3B
Q2 24
$273.3M
$9.8B
Q1 24
$269.3M
$9.9B
Total Assets
CSGS
CSGS
RPRX
RPRX
Q4 25
$1.5B
$19.6B
Q3 25
$1.5B
$19.3B
Q2 25
$1.4B
$18.3B
Q1 25
$1.4B
$17.6B
Q4 24
$1.5B
$18.2B
Q3 24
$1.4B
$18.0B
Q2 24
$1.4B
$17.7B
Q1 24
$1.3B
$16.1B
Debt / Equity
CSGS
CSGS
RPRX
RPRX
Q4 25
1.90×
0.92×
Q3 25
1.86×
0.93×
Q2 25
1.85×
0.84×
Q1 25
1.90×
0.78×
Q4 24
1.91×
0.74×
Q3 24
1.87×
0.74×
Q2 24
1.98×
0.78×
Q1 24
2.01×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSGS
CSGS
RPRX
RPRX
Operating Cash FlowLast quarter
$59.2M
$827.1M
Free Cash FlowOCF − Capex
$55.8M
FCF MarginFCF / Revenue
17.3%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
8.46×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$141.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSGS
CSGS
RPRX
RPRX
Q4 25
$59.2M
$827.1M
Q3 25
$47.9M
$702.6M
Q2 25
$37.3M
$364.0M
Q1 25
$11.5M
$596.1M
Q4 24
$82.5M
$742.5M
Q3 24
$39.5M
$703.6M
Q2 24
$43.1M
$658.2M
Q1 24
$-29.4M
$664.6M
Free Cash Flow
CSGS
CSGS
RPRX
RPRX
Q4 25
$55.8M
Q3 25
$43.9M
Q2 25
$34.6M
Q1 25
$7.1M
Q4 24
$76.6M
Q3 24
$32.0M
Q2 24
$38.8M
Q1 24
$-34.1M
FCF Margin
CSGS
CSGS
RPRX
RPRX
Q4 25
17.3%
Q3 25
14.5%
Q2 25
11.6%
Q1 25
2.4%
Q4 24
24.2%
Q3 24
10.8%
Q2 24
13.4%
Q1 24
-11.6%
Capex Intensity
CSGS
CSGS
RPRX
RPRX
Q4 25
1.1%
Q3 25
1.3%
Q2 25
0.9%
Q1 25
1.5%
Q4 24
1.9%
Q3 24
2.5%
Q2 24
1.5%
Q1 24
1.6%
Cash Conversion
CSGS
CSGS
RPRX
RPRX
Q4 25
8.46×
3.86×
Q3 25
2.34×
2.44×
Q2 25
3.04×
12.06×
Q1 25
0.71×
2.50×
Q4 24
2.39×
3.57×
Q3 24
2.07×
1.29×
Q2 24
3.12×
6.45×
Q1 24
-1.51×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSGS
CSGS

Software As A Service And Related Solutions$287.2M89%
License And Service$22.6M7%
Maintenance$13.3M4%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons